About Us
Crescendo Biologics is focused on novel immune cell enhancing therapeutics in immuno-oncology
Crescendo Biologics’ novel, targeted immune cell enhancing therapeutics are underpinned by its novel, patent-protected Humabody® VH platform, which is clinically validated in oncology and immunology.
Some of the key Humabody VH platform benefits include:
- Rapid discovery process
- Fully human VH domains (Humabodies) – no humanisation step is required
- Exceptional diversity and excellent hit rates
- Small size with ability to reach epitopes that monoclonal antibodies cannot
- Clearly differentiated tissue accumulation and tissue penetration compared to conventional monoclonal antibodies
- Robust chemical and physical stability
- Easily assembled into multi-specific formats (MultiBody®s), which can be formatted to access novel biology
- Tuneable half-life
- Multiple administration routes
- Excellent expression yields and established manufacturing processes
Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab.
Crescendo Biologics is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.